EUVIMEDEUVIMED entdecken
Fallbericht

Down-regulated Th17 cells in a patient with familial Mediterranean fever associated with amyloid A amyloidosis in the treatment of canakinumab

Takeshi Goto, Yusuke Miyazaki, Shingo Nakayamada, Naoki Shiraishi, Takeshi Yoshinaga, Yoshiya Tanaka, Tadashi Nakamura iD

Modern Rheumatology Case Reports · 03.01.2023 · 7 (1) · 237-242

DOI: 10.1093/mrcr/rxac031 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Modern Rheumatology Case Reports, online erschienen am 29.03.2022. Verfasst von Takeshi Goto und 6 weiteren Autor:innen. Beteiligte Einrichtung: Kumamoto University School of Medical Sciences, Kumamoto, Japan. Hauptthemen laut MEDLINE: Familial Mediterranean Fever. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 44 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Autoinflammatory diseases are innate immune-mediated inflammatory disorders, unlike autoimmune diseases, which are characterised by abnormalities in adoptive immunity, although autoimmune and autoinflammatory diseases have certain similar clinical features. Familial Mediterranean fever (FMF), the most common monogenic autoinflammatory disease, is associated with mutations in the MEFV gene that encodes pyrin, which results in inflammasome activation and uncontrolled production of interleukin (IL)-1β. Regular use of colchicine, the primary drug for FMF treatment, prevents febrile attacks and reduces the long-term risk of subsequent complications of amyloid A (AA) amyloidosis. However, a minority of FMF patients develop colchicine resistance, and anti-IL-1β treatment with canakinumab, which is a genetically modified human IgG subclass type 1 (IgG1) monoclonal antibody specific for human IL-1β, was beneficial in inhibiting inflammation in such patients. Here, we present a patient with FMF associated with AA amyloidosis, who was treated with canakinumab and demonstrated down-regulated Th17 cells and activated Th17 cells (from 21.4% to 12.8%, and from 1.45% to 0.83%, respectively) in peripheral blood, as shown by immunophenotyping via multicolour flow cytometry and by disease activity and improved laboratory inflammatory surrogate markers—C-reactive protein (CRP) and serum AA protein (SAA). CRP had values within normal limits, but SAA did not (Spearman’s rank correlation coefficient; ρ = 0.133). We report that SAA and IL-1β may differentiate Th17 cells from CD4+-naïve T cells, and we discuss interactions between autoinflammation and autoimmunity as a model based on this case, through modes of action with IL-1β and SAA. This report is the first demonstrating that an IL-1β antagonist may reduce Th17 cells in FMF as a therapeutic option.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Familial Mediterranean FeverHumansTh17 CellsInterleukin 1 Receptor Antagonist ProteinColchicinePyrinAntibodies, Monoclonal, HumanizedSerum Amyloid A ProteinAmyloidosis

Stichwörter der Autor:innen

CanakinumabIL-1βTh17 cellsfamilial Mediterranean feverserum amyloid A protein

Substanzen

Interleukin 1 Receptor Antagonist ProteinColchicinePyrincanakinumabAntibodies, Monoclonal, HumanizedMEFV protein, humanSerum Amyloid A Protein

Autor:innen und Institutionen

  • Kumamoto University School of Medical Sciences, Kumamoto, Japan.
  • First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
  • Section of Nephrology, Sakurajyuji Hospital, Kumamoto, Japan.
  • Section of Pneumatology, Sakurajyuji Hospital, Kumamoto, Japan.
  • Section of Rheumatology, Sakurajyuji Hospital, Kumamoto, Japan.

ORCID-Profile: Tadashi Nakamura

Zitieren

APA

Goto, T., Miyazaki, Y., Nakayamada, S., Shiraishi, N., Yoshinaga, T., Tanaka, Y., & Nakamura, T. (2023). Down-regulated Th17 cells in a patient with familial Mediterranean fever associated with amyloid A amyloidosis in the treatment of canakinumab. Modern Rheumatology Case Reports, 7(1), 237-242. https://doi.org/10.1093/mrcr/rxac031

Vancouver

Goto T, Miyazaki Y, Nakayamada S, Shiraishi N, Yoshinaga T, Tanaka Y, et al. Down-regulated Th17 cells in a patient with familial Mediterranean fever associated with amyloid A amyloidosis in the treatment of canakinumab. Modern Rheumatology Case Reports. 2023;7(1):237-242. doi:10.1093/mrcr/rxac031

BibTeX
@article{Goto2023,
  author = {Goto, Takeshi and Miyazaki, Yusuke and Nakayamada, Shingo and Shiraishi, Naoki and Yoshinaga, Takeshi and Tanaka, Yoshiya and Nakamura, Tadashi},
  title = {Down-regulated Th17 cells in a patient with familial Mediterranean fever associated with amyloid A amyloidosis in the treatment of canakinumab},
  journal = {Modern Rheumatology Case Reports},
  year = {2023},
  volume = {7},
  number = {1},
  pages = {237--242},
  doi = {10.1093/mrcr/rxac031}
}
Kostenlos starten →